ANI PHARMACEUTICALS, INC Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
ANI PHARMACEUTICALS, INC (ANIP) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of -$1.71 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-03-11.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2021-03-11
- ANI PHARMACEUTICALS, INC adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2018 was -$1.71M.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|
| 2018-12-31 | -$1.71M 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |